Evidence map›Paper›PMID 40281710›Full record

ArticleBioengineering (Basel, Switzerland)2025

Kidney Disease Segmentation and Classification Using Firefly Sigma Seeker and MagWeight Rank Techniques.

Dilovan Asaad Zebari

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Dilovan Asaad ZebariComputer Science, College of Science, Nawroz University, Duhok 42001, Kurdistan Region, Iraq.ORCID 0000-0002-7643-6359

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deep learning models possess the ability to precisely analyze medical images such as MRI, CT scans, and ultrasound images. This automated diagnostic process facilitates the early detection of kidney disease by identifying any abnormalities or signs of disease. Consequently, it allows for timely intervention and treatment, while also reducing the need for manual interpretation by radiologists or clinicians. As a result, the diagnosis process is expedited, leading to improved efficiency in healthcare. The proposed technique focuses on enhancing parallel convolutional layer architectures in kidney disease segmentation through the utilization of advanced optimization techniques. This approach integrates Firefly Sigma Seeker and MagWeight Rank methodologies into the design of these architectures. The Firefly Sigma Seeker methodology dynamically adjusts key parameters related to standard deviation during training to enable early stopping in the initial phase. Subsequently, MagWeight Rank optimizes parameter weighting and ranking within the architecture to prune less important weights, thereby reducing computational time and overfitting. By leveraging these techniques, the parallel convolutional layers are specifically tailored for kidney disease segmentation tasks. Finally, the Multi-Stream Neural Network (MSNN) efficiently classifies kidney disease. Through extensive experimentation and evaluation on kidney disease segmentation datasets, a comparative analysis of different architectures was conducted in terms of segmentation accuracy, computational efficiency, and scalability. The proposed framework achieves optimal segmentation performance, with an accuracy of 98.2%, a minimized loss of 0.1, a reduced computational time of 15 min and 4 s, and successfully avoids overfitting.

Indexed as

early detectionFirefly Sigma SeekerMagWeight RankMulti-Stream Neural Network (MSNN)optimization techniquesparallel convolutional layers

Identifiers

PMID40281710
PMCPMC12025038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.